Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

This clinical trial is no longer recruiting patients.


A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer - CA018-003

Updated: 28 May, 2019   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 2


  • Gender(s)

  • 18-110

    Age Range

  • 34


  • Recruiting

Treatment Options

Study Arms
Experimental: Nivolumab and BMS-986205 Combination
Biological: Nivolumab Biological: BMS-986205
Active Comparator: Nivolumab and Ipilimumab Combination
Biological: Nivolumab Biological: Ipilimumab
Experimental: Nivolumab and Relatlimab Combination
Biological: Relatlimab Biological: Nivolumab

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Advanced Gastric Cancer - Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work - Must have at least 1 lesion with measurable disease Exclusion Criteria: - Patients/subjects with HER2 positive tumor that have not been treated with trastuzumab prior to enrollment - Must not have suspected or known central nervous system metastases unless adequately treated - Patients/subjects with autoimmune disease - Patients/subjects who need daily oxygen therapy Other protocol defined inclusion/exclusion criteria could apply

Have questions? Email Us

Have questions?
Email Us